Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma
About this trial
This is an interventional treatment trial for Mucosal Melanoma
Eligibility Criteria
Inclusion Criteria: Histological or cytological confirmed melanoma that is metastatic or unresectable; patients must have a history of cutaneous, mucosal or unknown primary site Patients who have received prior systemic cytotoxic chemotherapy for treatment of melanoma are ineligible; the following groups are eligible with regard to prior systemic therapy either in the adjuvant or metastatic disease setting: No prior therapy Immunotherapy consisting of interferon, interleukin-2, granulocyte macrophage colony-stimulating factor (GM-CSF) or vaccine One prior investigational therapy (cannot be chemotherapy or an inhibitor of rat sarcoma [Ras], serine/threonine kinase [Raf], or mitogen-activated protein kinase kinase [MEK]) NOTE: Chemotherapy given via isolated limb perfusion is allowed Prior radiation therapy is allowed; however, if radiation has been administered to a lesion, there must be radiographic evidence of progression of that lesion in order for that lesion to constitute measurable disease or to be included in the measured target lesions All sites of disease must be evaluated within 4 weeks of registration; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 White blood count >= 3,000/mm^3 Absolute granulocyte count >= 1,500/mm^3 Platelet count >= 100,000/mm^3 Serum creatinine =< 2.0 x upper limit of normal (ULN) or serum creatinine clearance (CrCl) >= 40 ml/min (neither drug is cleared by the kidney) Total bilirubin =< 1.5 x ULN (< 3.0 x ULN in the presence of Gilbert's disease) Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 ULN in the presence of liver metastases) International normalized ratio (INR) =< 1.5 and a partial thromboplastin time (PTT) within normal limits (patients who are on therapeutic anticoagulation with warfarin should have documentation of a normal prothrombin time [PT]/PTT prior to initiating that therapy) Patients must not have ocular melanoma Patients must have discontinued immunotherapy or radiation therapy at least 4 weeks prior to initiation of treatment and recovered from adverse events due to those agents Patients must not receive any other investigational agents during the period on study or the four weeks prior to initiation of treatment Patients must not have a history or clinical evidence of brain metastasis; patients must be evaluated with a head magnetic resonance imaging (MRI) within 4 weeks prior to enrollment Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for >= 5 years prior to the time of randomization Patients must not have any evidence of bleeding diathesis Patients must not have a serious intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, clinically significant cardiovascular disease (e.g. uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 1 year prior to study entry, or psychiatric illness/social situations that would limit compliance with study requirements Patients must not be taking cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital), rifampin or St. John's Wort Women must not be pregnant or breast-feeding All females of childbearing potential must have a blood test or urine study within 4 weeks prior to registration to rule out pregnancy Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant while participating in this study, she should inform her treating physician immediately; if a man impregnates a woman while participating in this study, he should inform his treating physician immediately as well Human immunodeficiency virus (HIV)-positive patients are excluded from the study
Sites / Locations
- University of Alabama at Birmingham Cancer Center
- Mercy Hospital Fort Smith
- University of Arkansas for Medical Sciences
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
- City of Hope Comprehensive Cancer Center
- Marin Cancer Care Inc
- UC San Diego Moores Cancer Center
- USC / Norris Comprehensive Cancer Center
- Bay Area Tumor Institute
- Saint Joseph Hospital - Orange
- Stanford Cancer Institute
- Kaiser Permanente-Redwood City
- Kaiser Permanente-Richmond
- Kaiser Permanente-Roseville
- Kaiser Permanente - Sacramento
- Kaiser Permanente-San Diego Mission
- Veterans Administration-San Diego Medical Center
- Kaiser Permanente-San Francisco
- California Pacific Medical Center-Pacific Campus
- Kaiser Permanente-Santa Teresa-San Jose
- Santa Rosa Memorial Hospital
- Kaiser Permanente Medical Center - Santa Clara
- Kaiser Permanente-Santa Rosa
- Kaiser Permanente-Vallejo
- The Medical Center of Aurora
- Boulder Community Hospital
- Penrose-Saint Francis Healthcare
- Porter Adventist Hospital
- Exempla Saint Joseph Hospital
- Presbyterian - Saint Lukes Medical Center - Health One
- Swedish Medical Center
- Sky Ridge Medical Center
- Longmont United Hospital
- North Suburban Medical Center
- Hartford Hospital
- Yale University
- Beebe Medical Center
- Christiana Care Health System-Christiana Hospital
- Holy Cross Hospital
- Broward Health Medical Center
- Southwest Florida Regional Medical Center
- University of Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
- Baptist Cancer Institute
- Jupiter Medical Center
- Lakeland Regional Cancer Center
- Mount Sinai Medical Center
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Florida Hospital Orlando
- Moffitt Cancer Center
- Phoebe Putney Memorial Hospital
- Piedmont Hospital
- Atlanta Regional CCOP
- Dekalb Medical Center
- Northeast Georgia Medical Center
- Medical Center of Central Georgia
- Southern Regional Medical Center
- South Georgia Medical Center
- University of Hawaii Cancer Center
- Swedish Covenant Hospital
- University of Chicago Comprehensive Cancer Center
- Decatur Memorial Hospital
- Advocate Sherman Hospital
- NorthShore University HealthSystem-Evanston Hospital
- Hinsdale Hematology Oncology Associates Incorporated
- Trinity Medical Center
- Memorial Medical Center
- Carle Cancer Center
- Carle Clinic-Urbana Main
- IU Health Bloomington
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
- Indiana University/Melvin and Bren Simon Cancer Center
- Franciscan Saint Anthony Health-Michigan City
- Saint Joseph Regional Medical Center-Mishawaka
- Memorial Hospital of South Bend
- Physicians' Clinic of Iowa PC
- Cedar Rapids Oncology Association
- Heartland Oncology and Hematology LLP
- Genesis Medical Center - East Campus
- Medical Oncology and Hematology Associates-Des Moines
- Medical Oncology and Hematology Associates-Laurel
- University of Iowa/Holden Comprehensive Cancer Center
- Cedar Valley Medical Specialists
- Cancer Center of Kansas - Chanute
- University of Kansas Cancer Center
- Kansas City CCOP
- Salina Regional Health Center
- Cancer Center of Kansas - Wellington
- Cancer Center of Kansas-Wichita Medical Arts Tower
- Cancer Center of Kansas - Main Office
- Central Maine Medical Center
- Greater Baltimore Medical Center
- Sinai Hospital of Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
- Johns Hopkins University/Sidney Kimmel Cancer Center
- Frederick Memorial Hospital
- Massachusetts General Hospital Cancer Center
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
- Commonwealth Hematology Oncology PC-Worcester
- Saint Joseph Mercy Hospital
- University of Michigan Comprehensive Cancer Center
- Oakwood Hospital and Medical Center
- Wayne State University/Karmanos Cancer Institute
- Saint John Hospital and Medical Center
- Hurley Medical Center
- Grand Rapids Clinical Oncology Program
- West Michigan Cancer Center
- William Beaumont Hospital-Royal Oak
- Oncology Care Associates PLLC
- Munson Medical Center
- Saint John Macomb-Oakland Hospital
- Unity Hospital
- Abbott-Northwestern Hospital
- North Memorial Medical Health Center
- Park Nicollet Clinic - Saint Louis Park
- Regions Hospital
- United Hospital
- Saint Francis Regional Medical Center
- Minnesota Oncology and Hematology PA-Woodbury
- Singing River Hospital
- Freeman Health System
- Center for Cancer Care and Research
- Mercy Hospital Saint Louis
- Saint Louis-Cape Girardeau CCOP
- Mercy Hospital Springfield
- CoxHealth South Hospital
- Montana Cancer Consortium NCORP
- Frontier Cancer Center and Blood Institute-Billings
- Nevada Cancer Research Foundation CCOP
- Dartmouth Hitchcock Medical Center
- Veterans Adminstration New Jersey Health Care System
- Hackensack University Medical CCOP
- Rutgers Cancer Institute of New Jersey
- Montefiore Medical Center-Wakefield Campus
- Hematology Oncology Associates of Central New York-East Syracuse
- Glens Falls Hospital
- Laura and Issac Perlmutter Cancer Center at NYU Langone
- MidHudson Regional Hospital of Westchester Medical Center
- Interlakes Foundation Inc-Rochester
- University of Rochester
- Stony Brook University Medical Center
- State University of New York Upstate Medical University
- Carolinas Medical Center/Levine Cancer Institute
- Duke University Medical Center
- Wayne Memorial Hospital
- East Carolina University
- Mid Dakota Clinic
- Sanford Medical Center-Fargo
- Altru Cancer Center
- Summa Akron City Hospital/Cooper Cancer Center
- Mercy Medical Center
- Aultman Health Foundation
- Adena Regional Medical Center
- The Christ Hospital
- Case Western Reserve University
- Cleveland Clinic Foundation
- Ohio State University Comprehensive Cancer Center
- Columbus CCOP
- Grant Medical Center
- Mount Carmel Health Center West
- Doctors Hospital
- Grady Memorial Hospital
- Cleveland Clinic Cancer Center Independence
- Saint Rita's Medical Center
- Licking Memorial Hospital
- Springfield Regional Medical Center
- Cleveland Clinic Wooster Specialty Center
- University of Oklahoma Health Sciences Center
- Cancer Care Associates
- Western Oncology Research Consortium
- Kaiser Permanente
- Geisinger Medical Center
- Delaware County Memorial Hospital
- Oncology Hematology Associates of Northern Pennsylvania
- PinnacleHealth Cancer Center-Community Campus
- Penn State Milton S Hershey Medical Center
- Saint Mary Medical and Regional Cancer Center
- University of Pennsylvania/Abramson Cancer Center
- Pennsylvania Hospital
- Thomas Jefferson University Hospital
- Fox Chase Cancer Center
- University of Pittsburgh Cancer Institute (UPCI)
- Pottstown Memorial Medical Center
- Hematology and Oncology Associates of North East Pennsylvania
- Scranton Hematology Oncology
- Geisinger Medical Group
- Chester County Hospital
- Jennersville Regional Hospital
- Lankenau Medical Center
- WellSpan Health-York Hospital
- Kent County Hospital
- Medical University of South Carolina
- McLeod Regional Medical Center
- Rapid City Regional Hospital
- Sanford Cancer Center-Oncology Clinic
- Erlanger Medical Center
- East Tennessee Baptist Hospital-Mercy Health Partners
- Vanderbilt University/Ingram Cancer Center
- University of Vermont College of Medicine
- Martha Jefferson Hospital
- University of Virginia Cancer Center
- Danville Regional Medical Center
- Virginia Oncology Associates-Hampton
- Group Health Cooperative-Seattle
- Swedish Medical Center-First Hill
- West Virginia University Charleston
- Edwards Comprehensive Cancer Center
- Saint Mary's Medical Center
- West Virginia University Healthcare
- Fox Valley Hematology and Oncology
- Aurora Cancer Care-Southern Lakes
- Gundersen Lutheran Medical Center
- Dean Hematology and Oncology Clinic
- University of Wisconsin Hospital and Clinics
- Holy Family Memorial Hospital
- Marshfield Clinic
- Froedtert and the Medical College of Wisconsin
- Sydney West Area Health Service-Westmead Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Arm I (paclitaxel, carboplatin, sorafenib tosylate)
Arm II (carboplatin, paclitaxel, placebo)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.